Zevra Therapeutics Inc. announced that four abstracts highlighting clinical data and real-world experience with MIPLYFFA® (arimoclomol) have been accepted for presentation at the 22nd Annual WORLDSymposium™, scheduled to take place February 2-6, 2026, in San Diego, California. Among the presentations, Dr. Caroline Hastings will deliver an oral presentation on four-year real-world safety and efficacy data of MIPLYFFA in patients with Niemann-Pick Disease Type C (NPC). Additional poster presentations will cover outcomes from the U.S. Early Access Program (EAP), multi-year subgroup analyses, and efficacy results from a randomized, placebo-controlled clinical trial. The results have not yet been presented and will be available to registered attendees during the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9631850) on January 26, 2026, and is solely responsible for the information contained therein.